Company intelligence / Profile preview
Tianjin Ever Union Biotechnology Co., Ltd.
Tianjin, China
- Ownership
- Private
- Development stage
- Other
01
Overview
The company has conducted a Phase 1 clinical trial (NCT03424629) to assess the safety and efficacy of Umbilical Cord-Derived Mesenchymal Stem Cells in moderate and severe plaque psoriasis patients. The trial involved randomizing participants into three groups: high-dose UC-MSCs, low-dose UC-MSCs, or methotrexate group[1][8].
- Therapeutic areas
- Dermatology
- Modalities
- Stem cell therapyUmbilical Cord Mesenchymal Stem Cells (UC-MSCs)
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Tianjin Ever Union Biotechnology Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tianjin Ever Union Biotechnology Co., Ltd..